Detailed narrative
Casdatifan's Best-in-Class Profile and Efficacy
Arcus Biosciences is positioning casdatifan as a best-in-class HIF-2 alpha inhibitor, citing its differentiated PK/PD profile and superior EPO production inhibition. Updated data from the ARC-20 study in late-line clear cell RCC showed a confirmed ORR of 45% for the 100mg QD cohort, an increase from 35% previously, and a median PFS of 15.1 months. This efficacy is noted as significantly higher than belzutifan's 5.6 months PFS in the same setting, achieved without the toxicities associated with TKIs.
Frontline RCC Strategy and TKI-Free Regimens
The company's frontline strategy for RCC focuses on developing TKI-free casdatifan regimens, specifically combining casdatifan with anti-PD-1 and potentially anti-CTLA-4. This approach aims to improve upon the 20-25% primary progression rate and approximately 12-month median PFS of current IO-only therapies. Early data from the casdatifan plus zim (anti-PD-1) cohort showed a 9% primary progression rate, supporting the feasibility of a TKI-sparing backbone. Market research indicates a 3x preference for IO/IO regimens over IO/TKI for casdatifan combinations.
PEAK-1 Phase III Study Progress
The PEAK-1 Phase III study, evaluating casdatifan plus cabozantinib versus cabozantinib alone in IO-experienced clear cell RCC, is actively enrolling. The study has a sole primary endpoint of PFS, designed for a relatively short time to readout. Management expects the upcoming LITESPARK-011 data for belzutifan plus lenvatinib to validate and de-risk the HIF-2 alpha class in earlier lines, thereby amplifying enthusiasm and driving PEAK-1 enrollment to completion by year-end 2026.
Immunology Portfolio Development
Arcus is advancing an immunology portfolio, leveraging its small molecule capabilities to target validated mechanisms. Two lead programs, an MRGPRX2 antagonist and a TNF inhibitor, are expected to enter the clinic in late 2026 or early 2027. The MRGPRX2 antagonist targets chronic urticaria and atopic dermatitis, aiming for improved potency and pharmacokinetics over competitors. The TNF inhibitor is designed to selectively prevent TNF receptor 1 activation, potentially offering a safer alternative to existing anti-TNF antibodies.
Financial Performance and Outlook
For Q4 FY25, Arcus reported $33 million in GAAP revenue, up from $26 million in Q3. R&D expenses were $121 million, down from $141 million in Q3. The company ended the quarter with $1 billion in cash and investments, significantly boosted by a $288 million financing in November. This financial position is projected to fund operations until at least the second half of 2028. Full-year 2026 GAAP revenue is guided to be between $45 million and $55 million, with operating expenses expected to decrease meaningfully.
Upcoming Milestones and Strategic Focus
Key upcoming events include ASCO GU presentations for casdatifan monotherapy and LITESPARK-011 data. Later in 2026, the company plans to present updated data for the casdatifan plus cabozantinib cohort and new data from the casdatifan plus zim cohort of ARC-20. Arcus aims to initiate a second Phase III study for casdatifan in the frontline setting by year-end 2026, informed by ongoing ARC-20 combination cohorts. The company also expects its two lead immunology programs to enter the clinic by early 2027.